Barrington Research Reaffirms "Outperform" Rating for OPKO Health (NASDAQ:OPK)

Barrington Research reissued their outperform rating on shares of OPKO Health (NASDAQ:OPK - Free Report) in a research note issued to investors on Monday, Benzinga reports. The brokerage currently has a $1.50 price target on the biotechnology company's stock.

OPK has been the subject of several other reports. StockNews.com downgraded shares of OPKO Health from a hold rating to a sell rating in a report on Friday, March 1st. Piper Sandler reiterated an overweight rating and issued a $5.00 target price on shares of OPKO Health in a research note on Monday. Finally, HC Wainwright reiterated a buy rating and issued a $3.00 target price on shares of OPKO Health in a research note on Wednesday, February 28th.

OPKO Health Stock Performance

Shares of OPK stock traded up $0.11 on Monday, reaching $1.31. The stock had a trading volume of 14,475,477 shares, compared to its average volume of 15,270,733. The firm has a market capitalization of $913.06 million, a price-to-earnings ratio of -5.32 and a beta of 1.81. The company has a quick ratio of 1.22, a current ratio of 1.55 and a debt-to-equity ratio of 0.15. OPKO Health has a 12 month low of $0.85 and a 12 month high of $2.24. The firm's 50-day moving average is $0.99 and its two-hundred day moving average is $1.26.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Tuesday, February 27th. The biotechnology company reported ($0.09) EPS for the quarter, hitting the consensus estimate of ($0.09). The company had revenue of $181.90 million for the quarter, compared to analysts' expectations of $177.53 million. OPKO Health had a negative net margin of 21.76% and a negative return on equity of 12.69%. The business's revenue for the quarter was down 1.9% on a year-over-year basis. During the same period last year, the firm earned ($0.11) earnings per share. On average, research analysts expect that OPKO Health will post -0.33 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost acquired 500,000 shares of the firm's stock in a transaction dated Monday, March 18th. The stock was purchased at an average cost of $0.87 per share, with a total value of $435,000.00. Following the completion of the acquisition, the chief executive officer now directly owns 210,968,225 shares of the company's stock, valued at $183,542,355.75. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other OPKO Health news, CEO Phillip Md Et Al Frost bought 500,000 shares of the business's stock in a transaction that occurred on Monday, March 18th. The stock was bought at an average cost of $0.87 per share, for a total transaction of $435,000.00. Following the completion of the transaction, the chief executive officer now owns 210,968,225 shares of the company's stock, valued at approximately $183,542,355.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Vice Chairman Elias A. Zerhouni bought 550,300 shares of the business's stock in a transaction that occurred on Friday, January 5th. The shares were acquired at an average price of $0.93 per share, with a total value of $511,779.00. Following the completion of the transaction, the insider now directly owns 20,327,814 shares of the company's stock, valued at approximately $18,904,867.02. The disclosure for this purchase can be found here. Over the last ninety days, insiders bought 8,993,015 shares of company stock valued at $8,479,069. Insiders own 47.26% of the company's stock.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently modified their holdings of OPK. Vanguard Group Inc. raised its stake in OPKO Health by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 39,751,293 shares of the biotechnology company's stock valued at $60,024,000 after purchasing an additional 428,520 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in OPKO Health by 7.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 428,310 shares of the biotechnology company's stock valued at $647,000 after purchasing an additional 29,117 shares in the last quarter. Barclays PLC raised its stake in OPKO Health by 307.6% during the fourth quarter. Barclays PLC now owns 768,078 shares of the biotechnology company's stock valued at $1,161,000 after purchasing an additional 579,657 shares in the last quarter. Weiss Multi Strategy Advisers LLC purchased a new stake in shares of OPKO Health in the fourth quarter valued at $1,057,000. Finally, Royal Bank of Canada raised its stake in shares of OPKO Health by 19.8% in the fourth quarter. Royal Bank of Canada now owns 304,411 shares of the biotechnology company's stock valued at $460,000 after acquiring an additional 50,248 shares during the period. 64.63% of the stock is currently owned by institutional investors.

OPKO Health Company Profile

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.